Today

Agents

Chat

Arena

Discover

More

App

Curis notifies press release availability on positive emavusertib update - CRIS News | Rallies

Curis notifies press release availability on positive emavusertib update

CRIS•2026-07-22

Webcast information

Webcast details were posted at Curis's investor relations website.

TakeAim CLL enrollment guidance

Curis said TakeAim CLL enrollment guidance for December 2026 data increased to 5-10 patients; 10 patients consented.

Updated clinical data for emavusertib

Curis released updated clinical data for emavusertib in its registrational TakeAim Lymphoma study in primary CNS lymphoma.

BTK inhibitor-naive PCNSL showed an 86% overall response rate across all patients as of July 1, 2026; 100% in evaluable patients.
BTK inhibitor-experienced PCNSL showed a 26% overall response rate across all patients; 33% in evaluable patients.

Related News

Zoetis Inc. <ZTS.N>: Morgan Stanley cuts target price to $99.00 from $115.00

ZTS•2026-07-22

Juniata Valley Financial Q2 FY26 net income rises 32% to $2.5 million; EPS climbs 31.6% to $0.5

JUVF•2026-07-22

Utz Brands expands authority to call special shareholder meetings in bylaw changes

UTZ

•

2026-07-22

LM Funding America publishes shareholder letter on strategic shift

LMFA•2026-07-22

Ozop Energy highlights Ballislife HYDRO Canada distribution deal with Shoot 360 partner, with CAD $13.75 million five-year minimums

OZSC•2026-07-22